PMID- 8874623
OWN - NLM
STAT- MEDLINE
DCOM- 19970116
LR  - 20111117
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 10
IP  - 10
DP  - 1996 Sep
TI  - Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human 
      leukocyte antigen B35 molecules.
PG  - 1075-83
AB  - OBJECTIVE: To identify HIV-1 cytotoxic T lymphocyte (CTL) epitopes presented by 
      human leukocyte antigen (HLA)-B35 molecules that are associated with the 
      accelerated progression of AIDS using a reverse immunogenetic approach. METHODS: 
      8-mer to 11-mer sequences carrying two anchor residues at position 2 and the 
      carboxy-terminus were selected from HIV-1SF2 strain. Sixty-four peptides matched 
      to these sequences were synthesized and tested by a peptide binding assay using 
      RMA-S-B*3501 cells. Peripheral blood lymphocytes (PBL) from two HIV-1-infected 
      donors carrying HLA-B35 were stimulated once-weekly with each HLA-B*3501 binding 
      peptide. The CTL activity of the cultured cells for the HLA-B35-positive target 
      cells loaded with the corresponding peptides was examined after the second and 
      fourth stimulation. Furthermore, the CTL activity of the cultured cells 
      possessing HLA-B*3501-restricted HIV-1 peptide-specific CTL activity were 
      examined for the HLA-B*3501-positive target cells infected with the recombinant 
      vaccinia virus containing corresponding HIV-1 gene. RESULTS: HIV-1 
      peptide-specific HLA-B*3501-restricted CTL was induced in PBL of HIV-1 infected 
      donors by in vitro stimulation with 11 out of 27 HLA-B*3501-binding HIV-1 
      peptides. The specific CTL induced with 10 peptides killed the cells infected 
      with recombinant vaccinia virus expressing the corresponding HIV-1 proteins. Out 
      of these HIV-1 peptide epitopes, two epitopes were also presented by HLA-B51 
      molecules. CONCLUSION: In addition to the four HLA-B35-restricted HIV-1 CTL 
      epitopes that have been previously reported, nine HLA-B35-restricted HIV-1 CTL 
      epitopes were identified in the present study. These multiple epitopes will be 
      useful in studies for immunopathogenesis of AIDS.
FAU - Shiga, H
AU  - Shiga H
AD  - Institute of Medical Science, University of Tokyo, Japan.
FAU - Shioda, T
AU  - Shioda T
FAU - Tomiyama, H
AU  - Tomiyama H
FAU - Takamiya, Y
AU  - Takamiya Y
FAU - Oka, S
AU  - Oka S
FAU - Kimura, S
AU  - Kimura S
FAU - Yamaguchi, Y
AU  - Yamaguchi Y
FAU - Gojoubori, T
AU  - Gojoubori T
FAU - Rammensee, H G
AU  - Rammensee HG
FAU - Miwa, K
AU  - Miwa K
FAU - Takiguchi, M
AU  - Takiguchi M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Epitopes)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B35 Antigen)
RN  - 0 (HLA-B51 Antigen)
RN  - 0 (Oligopeptides)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - *Antigen Presentation
MH  - *Cytotoxicity, Immunologic
MH  - *Epitopes
MH  - HIV-1/genetics/*immunology
MH  - HLA-B Antigens/immunology
MH  - HLA-B35 Antigen/*immunology
MH  - HLA-B51 Antigen
MH  - Humans
MH  - Mutation
MH  - Oligopeptides/genetics/immunology/metabolism
MH  - Protein Binding
MH  - Recombinant Proteins/immunology
MH  - T-Lymphocytes/*immunology
MH  - Vaccinia virus/genetics
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
PST - ppublish
SO  - AIDS. 1996 Sep;10(10):1075-83.